Paula
Rodríguez Otero

Consultora Médica

Foto de Paula

Foto de Universidad de Cantabria

Universidad de Cantabria

Santander, España

Universidad de Cantabria-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2024

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica

2022

Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)
Clinical Lymphoma, Myeloma and Leukemia